- SEC Filing
Save time and jump to the most important pieces.
- SEC Filing
https://www.sec.gov/ix?doc=/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results. Tesla posted weaker-than-expected earnings and sales results for its first quarter on Tuesday. The electric vehicle giant also announced plans to speed up the launch of new models. Tesla shares jumped 10.6% to $160.01 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) shares gained 49.4% to $0.2276 in pre-market trading after gaining over 8% on Tuesday. Zapata Computing Holdings Inc. (NASDAQ:ZPTA) gained 30.8% to $2.04 in pre-market trading after declining 10% on Tues
ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in incomeReceived Cash Milestone Incomes of $496,000 for the nine months ended September 30, 2024 FREMONT, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the third quarter ended September 30, 2024. Key Financial and Operational Highl
FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches. The payment, tied to ABVC's psychiatric disorder pipeli
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1. Significant Global Licensing Agreements: - Vitargus® Licensing: Along with
424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pha
SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)
SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)
SC 13G - ABVC BIOPHARMA, INC. (0001173313) (Subject)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M. The Licensed Products for MDD and ADHD, owned by ABVC and its su
FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam) as the new Chief Executive Officer (CEO). Dr. Uttam is very familiar with ABVC and their subsidiaries, because of his role as Chief Operating Officer & Chief Scientific Officer of BioKey, Inc., a GMP-certified facility owned by ABVC that provides its clients with integrated pharmaceutical services, including early-phase product development, formulation development, analytical development & d